Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

$- $(56,472)

Net income (loss)

per share:

Basic $0.98 $- $(0.21)

Diluted (1) $0.95 $(0.03) $(0.20)

Weighted average

shares outstanding:

Basic 267,276

Diluted (1) 275,522 9,686

FAS 123R GAAP As

Amortization Expense Reported

Income Statement

Classification:

Total revenues $1,100,061

Cost of products

and services sold $(6,514) $(272,313)

Selling, general

and administrative $(22,889) $(318,386)

Research and development $(12,585) $(262,797)

Amortization of

intangibles $(55,658) $(55,658)

Equity in income (loss)

of equity method investments $188

Minority interest $463

Gains (losses) on investments

in equity securities $775

Other $(160)

Investment income $14,870

Interest expense $(1,655)

Summary:

Income (loss) before income

taxes $(55,658) $(41,988) $205,388

(Provision for) benefit

from income taxes $25,957 $12,537 $(60,117)

Net income (loss) $(29,701) $(29,451) $145,271

Net income (loss) per share:

Basic $(0.11) $(0.12) $0.54 <
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 The ... (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & ... and studies the Major Market Drivers, Restraints, and Opportunities in ... , Asia-Pacific and Rest of World. ... Tables 22 Figures ...
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering.      ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
(Date:6/18/2013)... June 18, 2013 On June 11, ... released a final decision memorandum concluding that FDG ... subsequent management of anti-tumor strategy, and the agency ... National Oncological PET Registry (NOPR) was developed jointly by ... projects under the Coverage with Evidence Development (CED) program ...
Breaking Biology Technology:Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3
... 31 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... and Drug Administration (FDA) seeking approval to,market pegloticase in ... review. Savient,s filing includes data from both the six-month,placebo ... from the Open,Label Extension (OLE) study. The data set ...
... 31 /Xinhua-PRNewswire/ -- Sundia MediTech,Company, a Shanghai-based drug ... this year,s Deloitte Technology,Fast 50 China award, and ... 50 China Program was announced today in Shenzhen, ... 50 Program started in 1995 in San Jose. ...
... than a dozen employers in health care, employment continued to increase in ... like no one was searching for those new jobs. , ... Seattle, ... care field, with an average of 30,000 jobs created each month. Even ...
Cached Biology Technology:Savient Submits Biologics License Application (BLA) for pegloticase 2Savient Submits Biologics License Application (BLA) for pegloticase 3Savient Submits Biologics License Application (BLA) for pegloticase 4Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3
(Date:6/18/2013)... It is estimated that between 5% and 10% of ... is to say that these tumours are attributable to ... BRCA1 or BRCA2. In patients with these mutations, PARP ... encouraging results that make them a new option for ... the latest studies indicate that a fraction of these ...
(Date:6/18/2013)... LA, London (18 June 2013). A team of internationally ... by Dr Sarah Ellis from the University of Lincoln, ... Clinic, Wisconsin, U.S.A. were invited by the International Society ... Feline Practitioners (AAFP) to compile guidelines for veterinarians, owners ... the environmental needs of the domestic cat. The new ...
(Date:6/17/2013)... MA Women in the U.S. exposed to high levels ... likely to have a child with autism as women who ... study from Harvard School of Public Health (HSPH). It is ... and air pollution across the U.S. , "Our findings raise ... the women in our study lived in areas where risk ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... April 14, 2011 -- The number of couples struggling with ... assisted reproductive technologies, like in vitro fertilization (IVF), to get ... increase the risk of multiple pregnancies (i.e., twins or triplets), ... Twins and triplets are likely to be born prematurely, ...
... 2011 Ceelox, Inc. (OTCBB: CELO) announced today that ... to cloud applications using biometrics. Ceelox ID Online® utilizes ... an Internet server-based biometric software application. This enables users ... credentials, i.e. user name and password, compromised or stolen ...
... The following highlights summarize research papers that have been ... 1. Little Ice Age resulted from more than just ... measure of the amount of light the Sun puts out, ... especially when TSI is notably higher or lower than its ...
Cached Biology News:New study finds stronger regulations of in vitro fertilization may save lives 2Ceelox Provides Biometric Identity Access to Cloud Applications 2Ceelox Provides Biometric Identity Access to Cloud Applications 3AGU journal highlights -- April 13, 2011 2AGU journal highlights -- April 13, 2011 3AGU journal highlights -- April 13, 2011 4AGU journal highlights -- April 13, 2011 5AGU journal highlights -- April 13, 2011 6AGU journal highlights -- April 13, 2011 7
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: